Pacira BioSciences, Inc. (PCRX) key performance indicators and operating metrics (9 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Expirel Net Product Sales | 143.3M | FY2026-Q1 |
| Zilretta Net Product Sales | 26.8M | FY2026-Q1 |
| Iovera Net Product Sales | 6.2M | FY2026-Q1 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | 40.2M | FY2026-Q1 |
| Non-GAAP Net Income | 24.5M | FY2026-Q1 |
| Bupivacaine Liposome Injectable Suspension Sales to Third-Party Licensees | 1.2M | FY2026-Q1 |
| Non-GAAP Diluted Earnings Per Share | 0.57 USD_per_share | FY2025-Q4 |
| Expirel Volume Growth Year-over-Year | 7.00 percent | FY2025-Q4 |
| Non-GAAP Basic Earnings Per Share | 0.72 USD_per_share | FY2025-Q3 |
Back to PCRX overview · PCRX earnings · PCRX holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.